Rein Therapeutics is working with clinical sites to begin recruiting patients in the U.K. for its Phase 2 trial of LTI-03, a therapy candidate for idiopathic pulmonary fibrosis (IPF), after receiving approval from the country’s Medicines and Healthcare Products Regulatory Agency (MHRA). “This MHRA approval marks an important milestone not only for Rein, but also […] The post UK approves Phase 2 trial for IPF therapy candidate LTI-03 appeared first on Pulmonary Fibrosis News.
